drugset / Trial / NCT01191944
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this trial is to evaluate non-inferiority of pramipexole Extended release to Immediate release at 18 weeks on the primary efficacy endpoint (Unified Parkinson's Disease Rating Scale II+III) in Chinese PD patients who can be concomitantly treated with Levodopa .
Timeline
- Start
- 2010-08
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pramipexole | Unknown | 0.125 mg | Oral |
| Subject | Pramipexole | Unknown | 0.375 mg | Oral |
| Subject | Pramipexole | Unknown | 1 mg | Oral |
| Subject | Pramipexole | Unknown | 4.5 mg | Oral |